鞘氨醇-1-磷酸受体调节疗法在多发性硬化治疗中的研究进展

Advances in Sphingosine-1-phosphate Receptor Modulation Therapy in the Treatment of Multiple Sclerosis

多发性硬化是一种以中枢神经系统慢性炎症、脱髓鞘和轴突损伤为主要特征的自身免疫性疾病,发病机制至今仍未阐明。近10年来口服免疫调节治疗正在兴起,其中鞘氨醇-1-磷酸受体调节剂在多发性硬化的治疗中取得了令人瞩目的疗效。文中主要关注S1P/S1PR信号通路在治疗多发性硬化中的作用、机制和临床应用现状以及展望。

Multiple sclerosis(MS)is an autoimmune disease that is characterized by central nervous system inflammation,demyelination,axonal loss.The pathogenesis of MS has not yet been elucidated.During the past decade,oral immunomodulating therapies is popular.Sphingosine-1-phosphate receptor(S1PR)modulator therapy for MS has impressive efficacy.This review is focus on the mechanism of action of S1P/S1PR in MS,current status and future prospects.